DARA BioSciences (NASDAQ:DARA) has signed a Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management (CHMI), providing formulary status for the WellCare Group of Companies for Soltamoxoral solution, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer.
Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. WellCare is a leading provider of government sponsored healthcare programs. The inclusion of Soltamox on the Medicare Part D Formulary allows broad, affordable product access to WellCare members nationwide.
“We continue to actively pursue ways to provide physicians and patients access to our synergistic portfolio of oncology supportive care products,” Dr. David Drutz, CEO and CMO of DARA, said in a statement.
“Inclusion of Soltamox on WellCare’s National Medicare Part D Formulary opens the door for DARA to a vast network, and importantly, this Part D formulary coverage allows WellCare and DARA to better address the needs of breast cancer patients on tamoxifen,” he added.
